Developing treatment for spinal and bulbar muscular atrophy

Progress in Neurobiology

Volumn 99, Issue 3, 2012, Pages 257-261

  Fischbeck, Kenneth H ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

Androgen receptor; IGF 1; Kennedy's disease; Motor neuron disease; Polyglutamine disease; Spinal and bulbar muscular atrophy

Indexed keywords

ANDROGEN; ANDROSTANOLONE; DUTASTERIDE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; LEUPRORELIN; PLACEBO; SOMATOMEDIN C;

COHORT ANALYSIS; ENZYME INHIBITION; KENNEDY DISEASE; MUSCLE STRENGTH; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC ANIMAL;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MUSCULAR ATROPHY, SPINAL; MUSCULAR DISORDERS, ATROPHIC; PEPTIDES; RECEPTORS, ANDROGEN;

EID: 84869871913     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2012.05.012     Document Type: Review

References (34)

1. Banno H., Katsuno M., Suzuki K., Takeuchi Y., Kawashima M., Suga N., Takamori M., Ito M., Nakamura T., Matsuo K., Yamada S., Oki Y., Adachi H., Minamiyama M., Waza M., Atsuta N., Watanabe H., Fujimoto Y., Nakashima T., Tanaka F., Doyu M., Sobue G. Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Annals of Neurology 2009, 65:140-150.
2. Banno H., Katsuno M., Suzuki K., Tanaka F., Sobue G. Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy (SBMA). Cell and Tissue Research 2012, [epub ahead of print].
3. Bodner R.A., Outeiro T.F., Altmann S., Maxwell M.M., Cho S.H., Hyman B.T., McLean P.J., Young A.B., Housman D.E., Kazantsev A.G. Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:4246-4251.
4. Chevalier-Larsen E.S., O'Brien C.J., Wang H., Jenkins S.C., Holder L., Lieberman A.P., Merry D.E. Castration restores function and neurofilament alterations of aged symptomatic males in a transgenic mouse model of spinal and bulbar muscular atrophy. Journal of Neuroscience 2004, 24:4778-4786.
5. Fernández-Rhodes L.E., Kokkinis A.D., White M.J., Watts C.A., Auh S., Jeffries N.O., Shrader J.A., Lehky T.J., Li L., Ryder J.E., Levy E.W., Solomon B.I., Harris-Love M.O., La Pean A., Schindler A.B., Chen C.J., Di Prospero N.A., Fischbeck K.H. Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. The Lancet Neurology 2011, 10:140-147.
6. Katsuno M., Adachi H., Kume A., Li M., Nakagomi Y., Niwa H., Sang C., Kobayashi Y., Doyu M., Sobue G. Testosterone reduction prevents phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Neuron 2002, 35:843-854.
7. Katsuno M., Adachi H., Doyu M., Minamiyama M., Sang C., Kobayashi Y., Inukai A., Sobue G. Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nature Medicine 2003, 9:768-773.
8. Katsuno M., Banno H., Suzuki K., Takeuchi Y., Kawashima M., Yabe I., Sasaki H., Aoki M., Morita M., Nakano I., Kanai K., Ito S., Ishikawa K., Mizusawa H., Yamamoto T., Tsuji S., Hasegawa K., Shimohata T., Nishizawa M., Miyajima H., Kanda F., Watanabe Y., Nakashima K., Tsujino A., Yamashita T., Uchino M., Fujimoto Y., Tanaka F., Sobue G. Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 2010, 9:875-884.
9. La Spada A., Wilson E.M., Lubahn D.B., Harding A.E., Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991, 352:77-79.
10. Lehky T.J., Chen C.J., Di Prospero N.A., Rhodes L.E., Fischbeck K., Floeter M.K. Standard and modified statistical MUNE evaluations in spinal-bulbar muscular atrophy. Muscle and Nerve 2009, 40:809-814.
11. Lieberman A.P., Harmison G., Strand A.D., Olson J.M., Fischbeck K.H. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Human Molecular Genetics 2002, 11:1967-1976.
12. Lin H.K., Yeh S., Kang H.Y., Chang C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:7200-7205.
13. McCampbell A., Taylor J.P., Taye A.A., Robitschek J., Li M., Walcott J., Merry D., Sobue G., Fischbeck K.H. CREB-binding protein sequestration by expanded polyglutamine. Human Molecular Genetics 2000, 9:2197-2202.
14. McCampbell A., Taye A.A., Whitty L., Penney E., Steffan J.S., Fischbeck K.H. Histone deacetylase inhibitors reduce polyglutamine toxicity. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:15179-15184.
15. Minamiyama M., Katsuno M., Adachi H., Waza M., Sang C., Kobayashi Y., Tanaka F., Doyu M., Inukai A., Sobue G. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2004, 13:1183-1192.
16. Montie H.L., Cho M.S., Holder L., Liu Y., Tsvetkov A.S., Finkbeiner S., Merry D.E. Cytoplasmic retention of polyglutamine-expanded androgen receptor ameliorates disease via autophagy in a mouse model of spinal and bulbar muscular atrophy. Human Molecular Genetics 2009, 18:1937-1950.
17. Montie H.L., Pestell R.G., Merry D.E. SIRT1 modulates aggregation and toxicity through deacetylation of the androgen receptor in cell models of SBMA. Journal of Neuroscience 2011, 31:17425-17436.
18. Nedelsky N.B., Pennuto M., Smith R.B., Palazzolo I., Moore J., Nie Z., Taylor J.P. Native functions of the androgen receptor are essential pathogenesis in a Drosophila model of spinobulbar muscular atrophy. Neuron 2010, 67:936-952.
19. Palazzolo I., Burnett B.G., Young J.E., Brenne P.L., La Spada A.R., Fischbeck K.H., Howell B.W., Pennuto M. Akt blocks ligand binding and protects against expanded polyglutamine androgen receptor toxicity. Human Molecular Genetics 2007, 16:1593-1603.
20. Palazzolo I., Stack C., Kong L., Musaro A., Adachi H., Katsuno M., Sobue G., Taylor J.P., Sumner C.J., Fischbeck K.H., Pennuto M. Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 2009, 63:316-328.
21. Palazzolo I., Nedelsky N.B., Askew C.E., Harmison G.G., Kazantsev A.G., Taylor J.P., Fischbeck K.H., Pennuto M. B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. Journal of Neuroscience Research 2010, 88:2207-2216.
22. Pandey U.B., Nie Z., Batlevi Y., McCray B.A., Ritson G.P., Nedelsky N.B., Schwartz S.L., DiProspero N.A., Knight M.A., Schuldiner O., Padmanabhan R., Hild M., Berry D.L., Garza D., Hubbert C.C., Yao T.P., Baehrecke E.H., Taylor J.P. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the ubiquitin-proteasome system. Nature 2007, 447:859-863.
23. Parodi S., Pennuto M. Neurotoxic effects of androgens in spinal and bulbar muscular atrophy. Frontiers in Neuroendocrinology 2011, 32:416-425.
24. Pozzi P., Bendotti C., Simeoni S., Piccioni F., Guerini V., Marron T.U., Martini L., Poletti A. Androgen 5-alpha-reductase type 2 is highly expressed and active in rat spinal cord motor neurones. Journal of Neuroendocrinology 2003, 15:882-887.
25. Ranganathan S., Harmison G.G., Meyertholen K., Pennuto M., Burnett B.G., Fischbeck K.H. Mitochondrial abnormalities in spinal and bulbar muscular atrophy. Human Molecular Genetics 2009, 18:27-42.
26. Ranganathan S., Fischbeck K.H. Therapeutic approaches to spinal and bulbar muscular atrophy. Trends in Pharmacological Sciences 2010, 31:523-527.
27. Rhodes L.E., Freeman B.K., Auh S., Kokkinis A.D., La Pean A., Chen C., Lehky T.J., Schrader J.A., Levy E.W., Harris-Love M., Di Prospero N.A., Fischbeck K.H. Clinical features of spinal and bulbar muscular atrophy. Brain 2009, 132:3242-3251.
28. Schmidt B.J., Greenberg C.R., Allingham-Hawkins D.J., Spriggs E.L. Expression of X-linked bulbospinal muscular atrophy (Kennedy disease) in two homozygous women. Neurology 2002, 59:770-772.
29. Shimohata T., Nakajima T., Yamada M., Uchida C., Onodera O., Naruse S., Kimura T., Koide R., Nozaki K., Sano Y., Ishiguro H., Sakoe K., Ooshima T., Sato A., Ikeuchi T., Oyake M., Sato T., Aoyagi Y., Hozumi I., Nagatsu T., Takiyama Y., Nishizawa M., Goto J., Kanazawa I., Davidson I., Tanese N., Takahashi H., Tsuji S. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nature Genetics 2000, 26:29-36.
30. Takeyama K., Ito S., Yamamoto A., Tanimoto H., Furutani T., Kanuka H., Miura M., Tabata T., Kato S. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 2002, 35:855-864.
31. Taylor J.P., Fischbeck K.H. Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?. Trends in Molecular Medicine 2002, 8:195-197.
32. Waza M., Adachi H., Katsuno M., Minamiyama M., Sang C., Tanaka F., Inukai A., Doyu M., Sobue G. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nature Medicine 2005, 11:1088-1095.
33. Yang Z., Chang Y.J., Yu I.C., Yeh S., Wu C.C., Miyamoto H., Merry D.E., Sobue G., Chen L.M., Chang S.S., Chang C. ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nature Medicine 2007, 13:348-353.
34. Young J.E., Garden G.A., Martinez R.A., Tanaka F., Sandoval C.M., Smith A.C., Sopher B.L., Lin A., Fischbeck K.H., Ellerby L.M., Morrison R.S., Taylor J.P., La Spada A.R. Polyglutamine-expanded androgen receptor truncation fragments activate a Bax-dependent apoptotic cascade mediated by DP5/Hrk. Journal of Neuroscience 2009, 29:1987-1997.